Skip to main content
Log in

Glucagon-like peptide-1 receptor agonists and fracture risk—limitations to current knowledge

  • Letter to the Editor
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Zhang YS, Weng WY, Xie BC, Meng Y, Hao YH, Liang YM, Zhou ZK (2018) Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos Int 29:2639–2644. https://doi.org/10.1007/s00198-018-4649-8

    Article  CAS  PubMed  Google Scholar 

  2. Driessen JH, van Onzenoort HA, Starup-Linde J, Henry R, Burden AM, Neef C, van den Bergh JP, Vestergaard P, de Vries F (2015) Use of glucagon-like-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs. Calcif Tissue Int. https://doi.org/10.1007/s00223-015-0037-y

  3. Driessen JH, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh J, Vestergaard P, Henry RM (2016) The use of incretins and fractures - a meta-analysis on population-based real life data. Br J Clin Pharmacol 83:923–926. https://doi.org/10.1111/bcp.13167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mabilleau G, Mieczkowska A, Chappard D (2014) Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. J Diabetes 6:260–266. https://doi.org/10.1111/1753-0407.12102

    Article  CAS  PubMed  Google Scholar 

  5. Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J (2014) Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. Endocrine 48:107–115. https://doi.org/10.1007/s12020-014-0361-4

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Starup-Linde.

Ethics declarations

Conflict of interest

BL reports research grants (institution) from Amgen and Novo Nordisk. BL serves on advisory boards for Amgen, Eli Lilly, and UCB and has received honoraria for lecturing from Amgen, Eli Lilly, UCB, and TEVA.

TH has received lecture fees from Eli Lilly, Amgen, and Astra-Zeneca. JS-L reports personal fees from Gilead Sciences Denmark and personal fees from Eli Lilly Denmark, outside the submitted work.

Additional information

Publisher’s note

 Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hygum, K., Harsløf, T., Langdahl, B. et al. Glucagon-like peptide-1 receptor agonists and fracture risk—limitations to current knowledge. Osteoporos Int 30, 1709–1710 (2019). https://doi.org/10.1007/s00198-019-05013-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-019-05013-7

Navigation